- Research & Development
- GMP Contract Manufacturing
- Allergen Shop
2017 promises to be another exciting year for Biomay.
We are proud to have been named "Best in Allergy Therapeutic Development" in the prestigious Corporate Heathcare & Life Sciences Awards 2016 from Corporate LiveWire. This award underscores our quest for excellence in our extremely important area of medicine.
We are making great progress towards our goal to bring innovative allergy immunotherpay products to the marketplace. To this end, we have recently successfully completed an important phase IIb clinical trial with our lead product BM32.
This study evaluated the response of grass pollen allergic patients to different dose regimens of our product. The results clearly show that we now have found an optimal dose, which provides significant relief for patients from allergy symptoms immediately in the first pollen season after start of treatment. This is very important for the patients, as they want to feel the effect of their therapy as quickly as possible.
We expect that follow-on treatment with BM32 in subsequent years will require only very few injections and will be very similar to your annual flu shot. Obviously, we will have to demonstrate the validity of this concept in future clinicsl trials and we are commited to do so. We will work very hard now to bring BM32 into phase III pivotal trials. If all goes well, we expect BM32 to be available for grass pollen allergy sufferers in 2021.
In our highly successful research collaboration with the Medical University in Vienna, we have discovered that our trademark PCFiT vaccine technology has much broader utility in other applications than allergies. Consequently, we have spun out certain assets in the field of antiviral vaccines and diagnostics into a new company, Viravaxx AG, who will develop products for these viral diseases independently. Please visit the website www.viravaxx.eu to learn more about this exciting new venture.
Our GMP manufacturing services, especially for plasmid DNA, continues to grow very rapidly, as the demand form companies developing gene and cell therapies is vigorously expanding. We are currently considering an expansion of our manufacturing capacity to be able to meet this demand and to serve our customers even better. We will report on our plans and decisions in this regard later this year, so stay tuned!
Chief Executive Officer
Biomay AG reports positive results from a second Phase IIb trial with the innovative 3rd generation grass pollen allergy vaccine BM32 (26 Jan. 2017)
Biomay, a global leader in allergy immunotherapy, announced today that a second phase IIb study...